Abstract:Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths in China. The recent emergence of immunotherapy treatment options, such as the use of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors, has also led to a paradigm shift in the treatment of non-small cell lung cancer, and has provided promising directions for the treatment of small cell lung cancer. This review provides a summary of the developmental process of immunotherapy, especially immune checkpoint inhibitors in lung cancer, ongoing international and domestic clinical trials in this field, and the challenges and considerations related to the use of immunotherapy in Chinese patients with lung cancer, with the aim of providing detailed information for future immunotherapy-related clinical trials in China. Research regarding immune checkpoint inhibitors in China is several years behind similar research in several developed countries. However, although PD-1/PD-L1 inhibitor-related clinical trials remain in their early stages in China, increased efforts by Chinese clinicians, researchers, and government staff have been directed toward trying to introduce novel drugs into the clinical setting. Because of the specific characteristics of Chinese patients with lung cancer (such as high epidermal growth factor receptor mutation rates, later disease stages, and different toxicity profiles), large-scale clinical trials targeting the Chinese population or Chinese participation in multinational trials should be promoted. IMPLICATIONS FOR PRACTICE: As the leading cause of cancer-related morbidity and mortality, lung cancer is a major public health problem in China. Immunotherapy based on programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors may result in new treatment directions and a paradigm shift for Chinese patients with lung cancer. Although checkpoint inhibitor-related clinical trials remain in their early stages in China, increased efforts by Chinese clinicians, researchers, and government staff have been directed toward trying to introduce novel drugs into the clinical setting by encouraging the development of large-scale clinical trials targeting the Chinese population and promoting Chinese patients with lung cancer to participate in international trials.

Progress in Clinical Researches of Immunotherapy for Lung Cancer Targeting PD-1/PD-L1

New progress in immunotherapy of lung cancer

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Favorable Clinical Outcomes of Checkpoint Inhibitor-Based Combinations after Progression with Immunotherapy in Advanced Non-Small Cell Lung Cancer

[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].

Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Impact of Clinicopathological Features on the Efficacy of Immune Checkpoint Inhibitors Plus Conventional Treatment in Patients with Advanced Lung Cancer

Recent Advances and Challenges of Immune Checkpoint Inhibitors in Immunotherapy of Non-Small Cell Lung Cancer

Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Clinical cancer immunotherapy: Current progress and prospects

Advances in PD-1/PD-L1 inhibitors in treatment of non-small cell lung cancer

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer